Human embryonic stem cell-derived cardiomyocytes for drug safety testing

Posted by

GE Healthcare Life Sciences

View compelling data that shows how human embryonic stem cell derived Cytiva™ cardiomyocytes can be a powerful approach to assessing cardiac drug liabilities. Nick Thomas, Principal Scientist at GE Healthcare Life Sciences describes how hESC derived Cytiva cardiomyocytes: •are a valid model of cardiomyocytes from the human heart •are compatible with assays routinely used for testing cardiotoxicity •together with high-content assays and analysis, can indicate the mechanism of toxicity of drug compounds.